Expected Moves

The Read: aTyr Pharma’s stock has historically declined sharply after meeting earnings without positive surprises on cash runway or clinical data, briefly rallied on regulatory progress for efzofitimod, but then fell again following ambiguous Phase 3 results and unclear FDA feedback despite a well-received equity raise.